Propafenone in combination antiarrhythmic therapy for patients with catecholaminergic polymorphic ventricular tachycardia

Summary. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited channelopathy characterized by bidirectional and/or polymorphic ventricular tachycardia triggered by physical or emotional stress. CPVT is associated with a high mortality rate if left untreated. Although beta-blockers are the cornerstone of pharmacologic management for catecholaminergic polymorphic ventricular tachycardia, their efficacy as monotherapy is often limited. This limitation highlights the need to investigate combination antiarrhythmic therapies that may more effectively reduce the risk of arrhythmogenic events and sudden cardiac death.
Objective. To compare the efficacy and safety of beta-blocker monotherapy versus combination therapy (beta-blocker plus propafenone) in patients with catecholaminergic polymorphic ventricular tachycardia.
Materials and Methods. The study included 68 patients diagnosed with catecholaminergic polymorphic ventricular tachycardia during childhood. Efficacy criteria for the therapy included the absence of ventricular and supraventricular arrhythmias and the absence of arrhythmogenic events during treatment.
Results. Combined antiarrhythmic therapy with a beta-blocker and the class IC antiarrhythmic agent propafenone was significantly more effective in preventing stress-induced cardiac rhythm disturbances (p=0.00002) and arrhythmogenic events (p=0.02) compared to beta-blocker monotherapy.
Conclusions. These results indicate that combination therapy with a beta-blocker and propafenone is more effective over beta-blocker monotherapy in patients with catecholaminergic polymorphic ventricular tachycardia. Further research is warranted to confirm these findings and to assess the potential inclusion of propafenone in future international clinical guidelines for catecholaminergic polymorphic ventricular tachycardia management.

1. Roston T.M., Yuchi Z., Kannankeril P.J., Hathaway J., Vinocur J.M., Etheridge S.P., et al. The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: Findings from an international multicentre registry. Europace 2018; 20(3): 541–547. DOI: 10.1093/europace/euw389

2. Josephs K., Patel K., Janson C.M., Montagna C., McDonald V.T. Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia. Mol Genet Genomic Med. 2017; 5(6): 788–794. DOI: 10.1002/mgg3.323

3. Kulbachinskaya E.K., Bereznitskaya V.V. CASQ2: clinical and genetic insights into catecholaminergic polymorphic ventricular tachycardia across three families. Al’manah klinicheskoj mediciny 2023; 51(3): 192–199. DOI 10.18786/2072–0505–2023–51–022.

4. Webster G., Aburawi E.H., Chaix M.A., Chandler S., Foo R., Monwarul Islam A.K.M., et al. Life-threatening arrhythmias with autosomal recessive TECRL variants. Europace 2021; 23(5): 781–788. DOI: 10.1093/europace/euaa376

5. Wang G., Zhao N., Zhong S., Wang Y., Li J. Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: A systematic review and meta-analysis. Medicine 2019; 98(34): p e16961. DOI: 10.1097/MD.0000000000016961

6. Galimberti E.S., Knollmann B.C. Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. J Mol Cell Cardiol 2011; 51(5): 760–768. DOI: 10.1016/j.yjmcc.2011.07.002

7. Marx A., Lange B., Nalenz C., Hoffmann B., Rostock T., Konrad T. A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone. HeartRhythm Case Reports 2019; 5(2): 74–77. DOI: 10.1016/j.hrcr.2018.04.003

8. Li S., Lv T., Yang J., Li K., Yang Y., Zhang P. A gain of function ryanodine receptor 2 mutation (R1760W-RyR2) in catecholaminergic polymorphic ventricular tachycardia. Clin Exp Pharmacol Physiol 2023; 50 (1): 39–49. DOI: 10.1111/1440–1681.13722

9. Veith M., El-Battrawy I., Roterberg G., Raschwitz L., Lang S., Wolpert C., et al. Long-Term Follow-Up of Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. J Clin Med. 2020; 9(4): 123–131. DOI: 10.3390/jcm9040903

10. Zeppenfeld K., Tfelt-Hansen J., de Riva M., Winkel B.G., Behr E.R., Blom N.A., et al. Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J, 2022. 43(40): p. 3997–4126. DOI: 10.1161/CIR.0000000000000548

11. Duan H., Lu Y., Yan S., Qiao L., Hua Y., Li Y., et al. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. Medicine (Baltimore) 2018; 97(16): 63–68. DOI: 10.1097/MD.0000000000010368

12. Friday K.P., Moak J.P., Fries M.H., Iqbal S.N. Catecholaminergic Ventricular Tachycardia, Pregnancy and Teenager: Are They Compatible? Pediatric Cardiology 2015; 36(7): 1542–1547. DOI: 10.1007/s00246–015–1232–3

13. Hwang H.S., Hasdemir C., Laver D., Mehra D., Turhan K., Faggioni M., et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class i antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circulation: Arrhythmia and Electrophysiology 2011; 4(2): 128–135. DOI: 10.1161/CIRCEP.110.959916

14. Lawrenz W., Krogmann O.N., Wieczorek M. Complex atrial arrhythmias as first manifestation of catecholaminergic polymorphic ventricular tachycardia: an unusual course in a patient with a new mutation in ryanodine receptor type 2 gene. Cardiol Young 2014; 24 (4): 741–744. DOI: 10.1017/S1047951113001091

15. Kulbachinskaya E., Bereznitskaya V. Long-term clinical course of patients with catecholaminergic polymorphic ventricular tachycardia: A more than 10-year follow-up cohort study. Annals of Pediatric Cardiology 2024; 17 (3): 196–203. DOI: 10.4103/apc.apc_101_24